Support the COVID-19 Emergency FundUpdated visitor policy; the latest newsLearn more
BOSTON – The Sean M. Healey & AMG Center for ALS at Mass General has received approval from the U.S. Food and Drug Administration (FDA) to proceed with administering three proposed drug regimens in the HEALEY ALS Platform Trial – the first trial of its kind for amyotrophic lateral sclerosis (ALS).
This symposium is a 2 day educational and networking forum designed for physicians,nurses, advanced practitioners, pharmacists, allied health professionals, researchers,and students with a focus on the emerging science of genetic therapies and theevaluation, management, and treatment of Alzheimer's Disease, ALS, brain tumors and metastases, and stroke.
The ALS Association today announced a $3 million commitment to the first platform trial for ALS, taking place at the Sean M. Healey & AMG Center for ALS at Mass General in collaboration with the Barrow Neurological Institute and the Northeast ALS Consortium (NEALS). A
Highlights from the meeting included a robust discussion moderated by Dr. Robert Brown with guest speakers Drs. Jean-Pierre Julien, from Laval Universities Department of Psychiatry and Neuroscience, Saud Sadiq, Director and Chief Research Scientist from Tisch MS Research Center of New York and Laura Paulsen, from EnClear Therapies, who spoke on the role of CSF toxicity in ALS pathophysiology.
The Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital (MGH) awarded the inaugural annual Healey Center International Prize for Innovation in amyotrophic lateral sclerosis (ALS) to the team that brought to trial the first antisense oligonucleotide (ASO) therapy for ALS. Team members include researchers from academia and industry.
Treatment with an anti-inflammatory drug delayed the onset of disease in a mouse model of ALS.
Congratulations to Merit Cudkowicz, MD, MSc, Director of the Sean M. Healey and AMG Center for ALS and Chief of Neurology at Mass General, who presented “A Powerful Promise,” a keynote speech at Accelerating Transformation, the 2019 Press Ganey National Client & Executive Leadership Conference in Orlando, Florida on Tuesday, November 18th.
Thank you to ALS ONE for the generous donation to the Healey Center for ALS! These funds will help us achieve our mission to boldly accelerate the development of effective treatments for ALS, through both lab-based and clinical research.
Friends and family of Healey Center for ALS patient Kathleen McCarron fielded a fundraising team for the Bourbon Chase Ragnar Race.
Members of the Northeast Amyotrophic Lateral Sclerosis Consortium assembled at the Opal Sands Resort, in Clearwater, Florida on October 2nd through October 4th for their 18th Annual Scientific Symposium.
Research at Massachusetts General Hospital integrates the full spectrum of "bench to bedside" discovery. Laboratory scientists work collaboratively with clinicians to make discoveries and turn them into treatments, diagnostics and devices that improve our quality of life.